HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: breakthrough HHV-6 encephalitis following antiviral prophylaxis.

Abstract
High incidences of human herpesvirus (HHV)-6 encephalitis have recently been reported from several Japanese SCT centers. To evaluate the effect of low-dose foscarnet (PFA) in preventing HHV-6 infection among recipients of unrelated BM or cord blood (CB), we examined consecutive cohorts without prophylaxis against HHV-6 (cohort 1, n=51) and with PFA prophylaxis (cohort 2, PFA 50 mg/kg/day for 10 days after engraftment, n=67). Plasma real-time PCR assay was performed weekly. High-level reactivation defined as HHV-6 DNA > or =10(4) copies/mL by day 70 was the primary endpoint. No significant reduction of high-level reactivation was seen in cohort 2 (19.4%) compared with cohort 1 (33.8%, P=0.095). A trend was identified toward fewer high-level HHV-6 reactivations in cohort 2 among recipients of unrelated BM (P=0.067), but no difference in incidence was observed among CB recipients (P=0.75). Breakthrough HHV-6 encephalitis occurred following PFA prophylaxis in three patients, and incidence of HHV-6 encephalitis did not differ between cohort 1 (9.9%) and cohort 2 (4.5%, P=0.24). In conclusion, 50 mg/kg/day of PFA does not effectively suppress HHV-6 reactivation and cannot prevent all cases of HHV-6 encephalitis. To effectively prevent HHV-6 encephalitis, alternative approaches based on the pathogenesis of HHV-6 encephalitis will probably be required.
AuthorsM Ogata, T Satou, Y Inoue, K Takano, T Ikebe, T Ando, J Ikewaki, K Kohno, A Nishida, M Saburi, Y Miyazaki, E Ohtsuka, Y Saburi, T Fukuda, J Kadota
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 48 Issue 2 Pg. 257-64 (Feb 2013) ISSN: 1476-5365 [Electronic] England
PMID22750998 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • Foscarnet
Topics
  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents (therapeutic use)
  • Cohort Studies
  • Encephalitis, Viral (drug therapy, etiology, prevention & control, virology)
  • Foscarnet (therapeutic use)
  • Hematopoietic Stem Cell Transplantation (adverse effects, methods)
  • Herpesvirus 6, Human (physiology)
  • Humans
  • Incidence
  • Middle Aged
  • Roseolovirus Infections (drug therapy, etiology, prevention & control, virology)
  • Transplantation, Homologous
  • Virus Activation (drug effects)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: